Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L10 pseudogene 6 (RPL10P6) is classified as a pseudogene within the human genome. Pseudogenes are DNA sequences that are similar to known genes but are not translated into functional proteins due to mutations, truncations, or lack of regulatory elements. RPL10P6 is related to the ribosomal protein L10 family, but unlike functional ribosomal protein genes (such as RPL10), it does not encode a protein involved in ribosome structure or function. There is no evidence that RPL10P6 plays a role in protein synthesis, serves as a therapeutic target, or contributes to human disease or drug response[7][8]. Other ribosomal protein pseudogenes, such as RPLP0P6, share similar functional null status[5]. The designation of RPL10P6 as a therapeutic target or biological molecule would be incorrect, as this pseudogene does not produce a protein or fulfill functional roles in cell biology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L10 pseudogene 6 (RPL10P6).